US › Healthcare

iSpecimen Inc (ISPC)

US · Healthcare · Diagnostics & Research

$2.15+6.97%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$156,009

Revenue YoY

-85.2%

Net profit

$-2.3M

Profit YoY

-37.2%

EPS

$-6.66

Net margin

-1,458.4%

Key statistics

Market cap

$2.7M

Forward P/E

0.0

P/B

3.34

Book value

$1.10

EPS (TTM)

$-329.05

52-week high

$103.20

52-week low

$1.77

50-day MA

$2.64

200-day MA

$11.20

Beta

1.63

Analyst view

Analysts rate iSpecimen Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $3.00.

Shareholding

Insiders

0.07%

Institutions

1.49%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	0.54%
Jane Street Group LLC	0.10%
UBS Group AG	0.09%
Citadel Advisors Llc	0.09%
Tower Research Capital LLC	0.01%
BlackRock Inc	0.00%
SBI Securities Co Ltd	0.00%
Sachetta LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for iSpecimen Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.